Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
275 Leser
Artikel bewerten:
(1)

Web Presence: Dr. Bryan White, MD Encourages Dosage Reduction Protocol for Antipsychotic Medications in Dementia Patients

Dr. Bryan White, MD is a practicing Internist in Dallas, TX who encourages reform and upgraded technologies to improve both physicians' and patients' experiences. Dr. White presented a dosage reduction protocol for antipsychotic medications in dementia patients to the Texas Medical Foundation open forum.

ARLINGTON, TX / ACCESSWIRE / November 5, 2019 / For decades, Dr. Bryan White, MD has championed better medical care and improved procedures in facilities across the country. He consistently encourages upgrades in technology and medication and often prompts doctors to seek alternative solutions or reduced dosages instead of relying on a one-size-fits-all type approaches to care.

Dr. Bryan White, MD graduated from the University of Texas Medical Branch School of Medicine in 1992, and he has been in practice for nearly 30 years now. He is Board Certified in Internal Medicine and a Diplomate of the Academy of Hospice and Palliative Medicine. Recognized for his distinguished work, White has also received a subspecialty board certification by the ABIM in Hospice and Palliative Medicine.

Dr. White has opened the discussion of dosage reduction protocols for antipsychotic medications in dementia patients. He first presented this idea to the Texas Medical Foundation open forum where it quickly gained traction among his peers. Open forums such as these allow professionals to propose ideas and collaborate on new solutions to improve care everywhere. Nursing home administrators and directors of nursing participated in Dr. White's conference call from all over the state.

"The Texas Medical Foundation is known for impactful campaigns and expert consultations that help improve physician offerings across the state," says Dr. Bryan White, MD. "It's the perfect environment for discussing a dosage reduction protocol for antipsychotic medications, especially in dementia patients."

The focus of the Texas Medical Foundation (TMF) is on promoting quality health and health care through contracts with federal, state, and local governments in addition to private organizations. TMF partners with providers in a variety of settings to ensure that every patient receives the appropriate care, every time.

The foundation has had an impactful history that extends back decades; in 1984, TMF was awarded the Medicare peer review organization contract to perform medical reviews for Medicare beneficiaries. Ever since, the contract has evolved to also include quality improvement activities in hospitals, nursing homes, physician offices and home health agencies. Recently, the foundation has expanded to offer consulting services to ensure quality care across the state.

"It was paramount that we addressed the use of antipsychotic medications in dementia patients--as dosage amounts didn't always align with the need," says Dr. Bryan White, MD. "These medications have been found to increase mortality in patients with dementia, many of whom live in nursing homes in Texas. I'm proud to say we are making real progress on this subject, and the protocol has already been successful in multiple facilities that provide care in locked units for people afflicted with dementia."

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence, LLC



View source version on accesswire.com:
https://www.accesswire.com/565363/Dr-Bryan-White-MD-Encourages-Dosage-Reduction-Protocol-for-Antipsychotic-Medications-in-Dementia-Patients

© 2019 ACCESS Newswire
Epische Goldpreisrallye
Der Goldpreis hat ein neues Rekordhoch überschritten. Die Marke von 3.500 US-Dollar ist gefallen, und selbst 4.000 US-Dollar erscheinen nur noch als Zwischenziel.

Die Rallye wird von mehreren Faktoren gleichzeitig getrieben:
  • · massive Käufe durch Noten- und Zentralbanken
  • · Kapitalflucht in sichere Häfen
  • · hohe Nachfrage nach physisch besicherten Gold-ETFs
  • · geopolitische Unsicherheit und Inflationssorgen

Die Aktienkurse vieler Goldproduzenten und Explorer sind in den vergangenen Wochen regelrecht explodiert.

Doch es gibt noch Titel, die Nachholpotenzial besitzen. In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Goldaktien jetzt besonders aussichtsreich sind und warum der Aufwärtstrend noch lange nicht vorbei sein dürfte.

Laden Sie jetzt den Spezialreport kostenlos herunter und profitieren Sie von der historischen Gold-Hausse.

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.